Interleukin-6 in renal disease and therapy

Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of th...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2015-04, Vol.30 (4), p.564-574
Main Authors: Jones, Simon A, Fraser, Donald J, Fielding, Ceri A, Jones, Gareth W
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Humans
Interleukin-6 - antagonists & inhibitors
Kidney Diseases - drug therapy
Kidney Diseases - metabolism
Kidney Diseases - pathology
Prognosis
Receptors, Interleukin-6 - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfu233